Lars Hedbys

Lars Hedbys is an accomplished professional in the life sciences sector with extensive experience in board-level positions. Currently serving as a Board Member at Xintela AB, Cell Invent AB, and Asgard Therapeutics, Lars also holds leadership roles, including Chairman of the Board at Strominnate Therapeutics AB and Chosa Oncology. Since 2006, Lars has been a Partner at Ventac Partners, a consulting firm specializing in commercialization, business development, and intellectual property strategy within the life sciences. Additional board memberships include RhoVac, Vetiqure AB, Scandinavian ChemoTech AB, and HAMLET Pharma. Lars holds a Ph.D. in Applied Biochemistry from The Faculty of Engineering at Lund University and an MSc in Chemical Engineering from Chalmers University of Technology.